Pulmatrix (PULM) S-4/A 1 May 15 Registration of securities issued in business combination transactions (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Dec. 31, 2014
Document Information [Line Items]
Document Type	S-4
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Entity Registrant Name	Ruthigen, Inc.
Entity Central Index Key	1574235
Entity Filer Category	Smaller Reporting Company

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Current Assets:
Cash	$11,570,000	$15,571,000	$96,000
Prepaid expenses and other current assets	199,000	3,000	4,000
Total Current Assets	11,769,000	15,574,000	100,000
Property and equipment, net	105,000	2,000	4,000
Deferred offering costs		0	44,000
Total Assets	11,874,000	15,576,000	148,000
Current Liabilities:
Accounts payable and accrued expenses	574,000	410,000	101,000
Payable to Former Parent	1,000	537,000	0
Total Current Liabilities	575,000	947,000	101,000
Commitments and contingencies
Stockholders' Equity:
Preferred stock, $0.0001 par value; 500,000 shares authorized; no shares issued and outstanding at December 31, 2014 and March 31, 2014	0	0	0
Common stock, $0.0001 par value; 100,000,000 shares authorized; 4,804,290 and 4,650,000 shares issued and outstanding at December 31, 2014 and March 31, 2014, respectively	480	465	200
Additional paid-in capital	20,104,520	18,297,535	597,800
Accumulated deficit	-8,806,000	-3,669,000	-551,000
Total Stockholders' Equity	11,299,000	14,629,000	47,000
Total Liabilities and Stockholders' Equity	$11,874,000	$15,576,000	$148,000

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Preferred Stock, Shares Authorized	500,000	500,000	500,000
Preferred Stock, Shares Issued	0	0	0
Preferred Stock, Shares Outstanding	0	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Common Stock, Shares Authorized	100,000,000	100,000,000	100,000,000
Common Stock, Shares, Issued	4,804,290	4,650,000	2,000,000
Common Stock, Shares, Outstanding	4,804,290	4,650,000	2,000,000

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Revenues	$0	$0	$0	$0	$0	$0
Operating Expenses
Research and development	619,000	395,000	1,924,000	1,065,000	1,382,000	258,000
Selling, general and administrative	1,097,000	263,000	3,226,000	1,064,000	1,736,000	265,000
Total Operating Expenses	1,716,000	658,000	5,150,000	2,129,000	3,118,000	523,000
Loss From Operations	-1,716,000	-658,000	-5,150,000	-2,129,000
Other Income
Interest income	4,000	0	13,000	0
Total Other Income	4,000	0	13,000	0
Net Loss	($1,712,000)	($658,000)	($5,137,000)	($2,129,000)	($3,118,000)	($523,000)
Net Loss Per Share
Basic and Diluted (in dollars per share)	($0.35)	($0.33)	($1.07)	($1.06)	($1.53)	($0.26)
Weighted Average Number of Common Shares Outstanding
Basic and Diluted (in shares)	4,848,145	2,000,000	4,806,735	2,000,000	2,036,301	2,000,000

CONDENSED_STATEMENT_OF_CHANGES

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Mar. 31, 2012	$0	$0	$28,000	($28,000)
Balance (in shares) at Mar. 31, 2012		0
Investment from Former Parent	570,000	0	570,000	0
Shares issued to Former Parent	0	200	-200	0
Shares issued to Former Parent (in shares)		2,000,000
Net loss	-523,000	0	0	-523,000
Balance at Mar. 31, 2013	47,000	200	597,800	-551,000
Balance (in shares) at Mar. 31, 2013		2,000,000
Investment from Former Parent	1,679,000	0	1,679,000	0
Shares and warrants issued for cash in connection with initial public offering	16,021,000	265	16,020,735	0
Shares and warrants issued for cash in connection with initial public offering (in shares)		2,650,000
Net loss	-3,118,000	0	0	-3,118,000
Balance at Mar. 31, 2014	14,629,000	465	18,297,535	-3,669,000
Balance (in shares) at Mar. 31, 2014		4,650,000
Shares issued for cash in connection with underwriter's exercise of overallotment, net	1,028,000	15	1,027,985	0
Shares issued for cash in connection with underwriter's exercise of overallotment, net (in shares)		154,290
Stock-based compensation	779,000	0	779,000	0
Net loss	-5,137,000	0	0	-5,137,000
Balance at Dec. 31, 2014	$11,299,000	$480	$20,104,520	($8,806,000)
Balance (in shares) at Dec. 31, 2014		4,804,290

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended				12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Mar. 31, 2014		Mar. 31, 2013
Cash Flows From Operating Activities
Net loss	($5,137,000)		($2,129,000)		($3,118,000)		($523,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	0		1,000		2,000		0
Stock-based compensation	779,000		0
Changes in operating assets and liabilities:
Prepaid expenses	-196,000		-248,000		1,000		-4,000
Accounts payable and accrued expenses	327,000		799,000		146,000		101,000
Net Cash Used in Operating Activities	-4,227,000		-1,577,000		-2,969,000		-426,000
Cash Flows From Investing Activities
Purchases of property and equipment	-103,000				0		-4,000
Net Cash Used in Investing Activities	-103,000		0		0		-4,000
Cash Flows From Financing Activities
Advances from Former Parent	0		916,000		1,453,000		0
Repayment of Former Parent advances	-536,000		0		-916,000		0
Payment of deferred offering costs	0		-1,116,000
Proceeds from issuance of common stock and warrants less issuance costs	865,000	[1]	0	[1]	16,228,000	[2]	-44,000	[2]
Investment from Former Parent	0		1,691,000		1,679,000		570,000
Net Cash Provided by Financing Activities	329,000		1,491,000		18,444,000		526,000
Net Decrease In Cash	-4,001,000		-86,000		15,475,000		96,000
Cash - Beginning	15,571,000		96,000		96,000		0
Cash - Ending	11,570,000		10,000		15,571,000		96,000
Non-cash operating and financing activities:
Accrued Offering Costs					$163,000		$0
[1]	Gross proceeds of initial public offering of $1,117,000 less $252,000 of offering costs, of which $89,000 was withheld from the proceeds and $163,000 was paid in cash that was previously accrued.
[2]	Gross proceeds of initial public offering of $19,216,000 less $3,195,000 of offering costs, of which $2,826,000 was withheld from the proceeds, $206,000 was paid in cash (including $44,000 paid during the fiscal year ended March 31, 2013) and $163,000 was accrued as of March 31, 2014.

CONDENSED_STATEMENTS_OF_CASH_F1

CONDENSED STATEMENTS OF CASH FLOWS [Parenthetical] (USD $)	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Gross Proceeds From Issuance Of Common Stock And Warrants	$1,117,000	$19,216,000
Offering Cost	252,000	3,195,000
Offering Cost Withheld From The Proceeds	89,000	2,826,000
Payments of Stock Issuance Costs	163,000	206,000	44,000
Accrued Offering Costs		$163,000	$0

Nature_of_Operations_and_Basis

Nature of Operations and Basis of Presentation	9 Months Ended
	Dec. 31, 2014
Nature Of Operations And Basis Of Presentation [Abstract]
Nature Of Operations And Basis Of Presentation Disclosure [Text Block]	Note 1. Nature of Operations and Basis of Presentation
	Ruthigen, Inc. (the “Company” or “Ruthigen”) is a biopharmaceutical company focused on pioneering new hypochlorus acid, or HOCl, based therapies designed to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures.
	The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of December 31, 2014. The results of operations for the three and nine months ended December 31, 2014 are not necessarily indicative of the operating results for the full year. It is recommended that these condensed financial statements be read in conjunction with the financial statements and related disclosures for the Company’s fiscal year ended March 31, 2014 included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (“SEC”) on June 30, 2014.

Organization

Organization	12 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Organization
	Organization
	Ruthigen, Inc. (the “Company” or “Ruthigen”) was incorporated under the laws of the State of Nevada on January 18, 2013. The Company was reincorporated from Nevada to Delaware on September 25, 2013. The Company’s principal office is located in Santa Rosa, California. Ruthigen is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade hypochlorous acid, or HOCl, based therapeutics designed to prevent and treat infection in invasive applications.
	The Company closed its initial public offering (“IPO”) on March 26, 2014, pursuant to which an aggregate of 2,650,000 units were sold at a price of $7.25 per unit. Prior to the IPO, the Company was a wholly-owned subsidiary of Oculus Innovative Sciences, Inc. (“Oculus” or “Former Parent”). See Note 6 Stockholders’ Equity — Initial Public Offering and Note 9 Subsequent Events for additional details.
	Expenses of the Company include those specifically identifiable to the Company, and in periods prior to the year ended March 31, 2014, expenses specifically identifiable to the Company and allocations of salaries and consulting expenses from Oculus. The allocated expenses were primarily based on the use of estimates. Expenses allocated from the Former Parent were costs which benefited the Company and were required for its operations. Certain general corporate expenses of the Former Parent were not allocated because they did not provide a direct or material benefit to the business. In addition, if the Company had been part of its Former Parent during the periods presented, such general corporate expenses incurred by the Former Parent would not have significantly changed as a result of not having to operate the business. In the opinion of management, the methods of allocating costs were reasonable; however such costs did not necessarily equal costs that the Company would have incurred on a stand-alone basis. Therefore, the financial information included herein may not necessarily reflect assets and liabilities and expenses and cash flows of the Company if operated on a stand-alone basis. To date, the Company has not generated any revenues from its operations.
	Reverse Stock Split
	On September 25, 2013, the board of directors and the stockholders of the Company approved a 1-for-2.5 reverse stock split of the Company’s outstanding common stock, $0.0001 par value, which was effected on September 25, 2013. In connection with the reverse stock split, every 2.5 shares of common stock were reclassified and combined into one share of common stock. The reverse stock split reduced the number of shares of common stock outstanding from 5,000,000 to 2,000,000. The total number of authorized common stock that the Company shall have the authority to issue as set forth in the Company’s Restated Certificate of Incorporation, as amended, was not proportionally decreased in connection with the reverse stock split.
	All common shares and per share amounts contained in the Company’s accompanying financial statements have been retroactively adjusted to reflect a 1-for-2.5 reverse stock split, effective as of September 25, 2013.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended					12 Months Ended
	Dec. 31, 2014					Mar. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies					Note 2. Summary of Significant Accounting Policies
	Liquidity and Financial Condition					Liquidity and Financial Condition
	The Company incurred net losses of $1,712,000 and $5,137,000 for the three and nine months ended December 31, 2014, respectively, and $658,000 and $2,129,000 for the three and nine months ended December 31, 2013, respectively. At December 31, 2014, the Company’s working capital and accumulated deficit were $11,194,000 and $8,806,000, respectively. The Company has not yet achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.					The Company incurred a net loss of $3,118,000 and $523,000 for the years ended March 31, 2014 and 2013, respectively. At March 31, 2014, the Company’s working capital and accumulated deficit were $14,627,000 and $3,669,000, respectively. The Company has not yet achieved profitability and it is expected that research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.
	The Company believes that its existing cash, which includes the proceeds from its initial public offering (“IPO”), will be sufficient to fund its operations through the quarter ending March 31, 2016. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means. The Company has not secured any commitment for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.					Subsequent to March 31, 2014, in connection with the exercise of the Over-Allotment Option (as defined in Note 6) by the lead underwriter in the Company’s IPO, 154,290 shares of common stock were sold for $1,028,000 of aggregate gross proceeds to the Company. The Company believes that its existing cash, which includes the proceeds from its IPO, will be sufficient to fund its operations into the quarter ending December 31, 2015. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means.
	Use of Estimates					The Company has not secured any commitment for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to the Company’s deferred tax assets and the expense allocations relating to the Company’s operations prior to its deconsolidation from Oculus Innovative Sciences, Inc. (“Oculus” or “Former Parent”) on March 26, 2014.					Use of Estimates
	Stock-Based Compensation					The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the expense allocations from the Former Parent and the valuation allowance related to the Company’s deferred tax assets.
	The Company accounts for share-based awards exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Company estimates the fair value of restricted stock and restricted stock units (“RSUs”) based upon the closing market price of the Company’s common stock on the date the award is granted. The Company amortizes the fair value of employee awards on a straight-line basis over the requisite service period of the awards. Stock-based compensation expense includes the impact of an estimate for forfeitures for all stock awards. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.					Concentration of Credit Risk
	The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over the requisite service period.					Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash. Cash is maintained in financial institutions located in the United States. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits.
	Net Loss Per Share					Fair Value of Financial Assets and Liabilities
	The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable.					Financial instruments, including cash, accounts payable and accrued expenses are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:					The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value:
						Level 1 — quoted prices in active markets for identical assets or liabilities.
						Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.
		December 31,				Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions).
		2014		2013		Property and Equipment
	Options		332,500		—	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification is as follows:
	Warrants		3,145,650		—
	Restricted stock units		352,529		—
	Total		3,830,679		—			Years
	Recent Accounting Pronouncements					Office Equipment		3
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation — Stock Compensation” as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its financial statements.					Manufacturing, lab and other equipment		5
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The guidance, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company does not believe adoption of this ASU will have a material effect on its condensed financial statements.					Furniture and fixtures		7
	Subsequent Events					Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
	Management has evaluated subsequent events or transactions occurring through the date these condensed financial statements were issued.					Impairment of Long-Lived Assets
						The Company periodically reviews the carrying values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment include, but are not necessarily limited to:
							•	a significant decrease in the fair value of an asset;
							•	a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;
							•	a significant adverse change in legal factors or in the business climate that affects the value of an asset;
							•	an adverse action or assessment by the U.S. Food and Drug Administration or another regulator;
							•	an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.
						When circumstances indicate that an impairment may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.
						Stock-Based Compensation
						The Company accounts for share-based awards exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock awards using the Black-Scholes valuation model. The Company amortizes the fair value of employee stock awards on a straight-line basis over the requisite service period of the awards. Compensation expense includes the impact of an estimate for forfeitures for all stock awards.
						The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over the requisite service period.
						Research and Development
						Research and development expense is charged to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies.
						Net Loss per Share
						The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
						As of March 31, 2014, outstanding stock warrants to purchase 3,140,250 shares of common stock were excluded from the calculation of diluted net loss per common share because their impact would have been anti-dilutive. As of March 31, 2013, the Company did not have any potentially dilutive securities outstanding.
						Income Taxes
						The Company accounts for income taxes under Accounting Standards Codification (“ASC”) 740 Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
						ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
						Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company’s financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company’s financial condition, results of operations or cash flows.
						Recent Accounting Pronouncements
						In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.” This ASU removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company has elected to adopt this ASU effective with this Annual Report on Form 10-K and its adoption resulted in the removal of previously required development stage disclosures.
						Subsequent Events
						Management has evaluated subsequent events or transactions occurring through the date these financial statements were issued (See Note 9 Subsequent Events).

Property_and_Equipment

Property and Equipment	12 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 3. Property and Equipment
	Property and equipment consists of the following:
		March 31,
		2014			2013
	Office Equipment	$	4,000		$	4,000
	Less: accumulated depreciation and amortization		(2,000	)		—
	Total	$	2,000		$	4,000
	Depreciation expense amounted to $2,000 and $0 for the years ended March 31, 2014 and 2013, respectively. Depreciation expense is reflected in selling, general and administrative expenses in the statements of operations.

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	9 Months Ended
	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Disclosure Of Prepaid Expenses And Other Current Assets [Text Block]	Note 3. Prepaid Expenses and Other Current Assets
	Prepaid expenses and other current assets consists of the following:
		December 31,		March 31,
		2014		2014
		(unaudited)
	Prepaid insurance	$	114,000	$	—
	Deposits		50,000		1,000
	Prepaid rent		1,000		2,000
	Other prepaid expenses and current assets		34,000		—
	Total	$	199,000	$	3,000

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	9 Months Ended					12 Months Ended
	Dec. 31, 2014					Mar. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 4. Accounts Payable and Accrued Expenses					Note 4. Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consists of the following:					Accounts payable and accrued expenses consist of the following:
		December 31,		March 31,			March 31,
		2014		2014			2014		2013
		(unaudited)				Accrued employee compensation	$	109,000	$	40,000
	Accrued employee compensation	$	72,000	$	109,000	Accrued director compensation		50,000		—
	Accrued director compensation		20,000		50,000	Accrued legal fees		183,000		18,000
	Accrued legal fees		75,000		183,000	Other accrued expenses		68,000		43,000
	Accrued professional fees		160,000		45,000	Total	$	410,000	$	101,000
	Accrued research and development		231,000		9,000
	Other accrued expenses		16,000		14,000
	Total	$	574,000	$	410,000

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 5. Commitments and Contingencies	Note 5. Commitments and Contingencies
	Employment Agreements	Employment Commitments
	On June 24, 2014, the compensation committee of the Company’s board of directors approved an employment agreement for its Chief Financial Officer (“CFO”), which replaced the offer letter previously in effect between the Company and the CFO. The employment agreement continues to provide for an annual base salary of $225,000, subject to increase, as determined by the Company’s board of directors. The employment agreement further provides for payments to the CFO in the event of termination without cause or resignation by the CFO for good reason, as such terms are defined in the employment agreement. In the event that the CFO is terminated without cause or resigns for good reason, the CFO is entitled to: (i) a lump severance payment equal to 18 times the average monthly base salary paid to the CFO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CFO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event the CFO resigns for good reason prior to a change of control, only the vesting of the restricted stock units granted by the Company on May 12, 2014 shall be accelerated. In addition, if the Company consummates a change of control, all equity awards granted by the Company that are then-outstanding and unvested shall become fully vested and exercisable immediately prior to and subject to the consummation of the change of control. In addition, the Company will reimburse the CFO for any excise taxes owed by the CFO under Section 280G and Section 4999 of the Internal Revenue Code because of any acceleration of the equity awards (including a gross up of any additional federal, state and local taxes payable as a result of the reimbursement of the tax payments).	The Company has an employment agreement in place with its Chief Executive Officer (“CEO”) that provides for, among other things, the payment of a lump sum severance benefit equal to twenty-four times the CEO’s average monthly base salary paid to the CEO during the twelve months preceding the date of termination. As of March 31, 2014, the CEO’s base salary was $375,000 per annum.
	On November 28, 2014, the compensation committee of the Company’s board of directors approved an amended and restated employment agreement for its Chief Executive Officer (“CEO”), which supersedes the employment agreement previously in effect between the Company and the CEO. The prior employment agreement went into effect when the Company was a wholly-owned subsidiary of Oculus, and the CEO was the Chairman of the board of directors of Oculus. The employment agreement primarily removes all references to Oculus and other legacy references related to Ruthigen being a subsidiary of Oculus.	On August 12, 2013, Oculus’ Compensation Committee approved the grant of a one-time cash bonus of $158,000 to the Company’s CEO in order to recognize the CEO’s efforts related to the preparation and filing of the Company’s registration statement on Form S-1 for its IPO.
	The employment agreement continues to provide for an annual base salary of $375,000 to the CEO, subject to increase, as determined by the Company’s board of directors. The employment agreement further provides for payments to the CEO in the event of termination without cause or resignation by the CEO for good reason, as such terms are defined in the employment agreement. In the event that the CEO is terminated without cause or resigns for good reason, the CEO is entitled to: (i) a lump severance payment equal to 24 times the average monthly base salary paid to the CEO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CEO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards. In addition, if the Company consummates a change of control, all equity awards granted by the Company that are then-outstanding and unvested shall become fully vested and exercisable immediately prior to and subject to the consummation of the change of control. In addition, the Company will reimburse the CEO for any excise taxes owed by the CEO under Section 280G and Section 4999 of the Internal Revenue Code because of any acceleration of the equity awards (including a gross up of any additional federal, state and local taxes payable as a result of the reimbursement of the tax payments). Furthermore, the Company will reimburse the CEO for relocation expenses if the Company’s principal executive offices are moved or the CEO is required to relocate, subject to certain conditions.	License and Supply Agreement
	Receipt of the termination benefits described above is contingent on the CEO’s execution of a general release of claims against the Company, its subsidiaries and its affiliates; the CEO’s resignation from any and all directorships and every other position held by the CEO with the Company and each of its subsidiaries; and the CEO’s return to the Company and its affiliates or the Company Group (as such term is defined in the employment agreement), of all property belonging to the Company Group, received from or on account of the Company Group, or any other entity of the Company Group, or any of the Company Group’s respective affiliates by the CEO. In addition, the CEO is not entitled to such benefits if the CEO does not comply with the non-competition, invention assignment, confidentiality, non-solicitation provisions of the employment agreement.	The Company entered into a license and supply agreement with Oculus which was effective upon the completion of the IPO, pursuant to which Oculus has agreed to exclusively license certain of its proprietary technology to the Company to enable the Company’s research, development and commercialization of newly discovered RUT58-60 and any improvements to it (the “Product”) in the United States, Canada, the European Union and Japan (collectively, the “Territory”) in certain invasive uses in humans (the “Field”) which do not include dermatologic uses or uses for ophthalmic, sinusitis or otic indications.
	As of December 31, 2014, the potential cash severance payment related to the Company’s employment agreements in place with its CEO and CFO amounted to $1,144,000.	In order to pay for the costs of development of the Product, Ruthigen obtained financing from Oculus until the IPO was completed. Under the agreement, the Company’s right to commercialize the Product in the Field in the Territory is exclusive and shall be performed in accordance with the development and commercialization plan set forth in the agreement (which may be modified by the Company’s discretion), and Oculus shall manufacture and supply, at a purchase price equal to 20% over the cost of goods to Oculus, the Product as and when the Company requests. In addition, the Company has the right to purchase certain manufacturing equipment from Oculus at a purchase price equal to a fixed percentage over the cost of the equipment to Oculus, so that the Company may manufacture the Product independently.
	License and Supply Agreement	Under the license and supply agreement, the Company will be required to make a total of $8 million of milestone payments to Oculus over the next several years for the first Product only, as follows: $1.5 million upon the completion of last patient enrollment in the Phase 1/2 clinical trial, $1.5 million upon the completion of last patient enrollment of the Company’s first pivotal trial, $3 million upon completion of the first meeting with the FDA following completion of the Company’s first pivotal clinical trial, and $2 million upon first patient enrollment in the second pivotal clinical trial. In addition, as further consideration under the agreement, the Company will be required to make royalty payments to Oculus based on its annual net sales of the Product from the date of first commercial sale to the date that the Company ceases to commercialize the Product, which percentage royalty rate will vary between 3% and 20% and will increase based on various net sales thresholds and will differ depending on the country in which the sales are made.
	The Company entered into a license and supply agreement with Oculus which was effective upon the completion of the IPO, pursuant to which Oculus has agreed to exclusively license certain of its proprietary technology to the Company to enable the Company’s research, development and commercialization of newly discovered RUT58-60 and any improvements to it in the United States, Canada, the European Union and Japan in certain invasive uses in humans which do not include dermatologic uses or uses for ophthalmic, sinusitis or otic indications. Under the license and supply agreement, the Company will be required to make a total of up to $8 million of milestone payments to Oculus over the next several years payable upon the completion of specified performance conditions. The Company will accrue for the milestone payment liability if and when the Company determines that the achievement of such conditions is probable. As of December 31, 2014, the Company has not accrued for any portion of the milestone payments.	The agreement contains representations and warranties of the parties regarding its enforceability, no conflict with agreements to which the parties are bound, and no violations of law, and representations of Oculus that it has not granted any other license with respect to the Product for use in the Field in the Territory. The Company has agreed to indemnify Oculus with respect to third party claims arising from the Company’s development, commercialization or manufacture of the Product in the Field in the Territory with certain exceptions, and the Company and Oculus have each agreed to indemnify the other with respect to third party claims arising from their respective inaccuracy and/or breach of representations and warranties or negligence or willful misconduct. Either party may terminate the agreement for an uncured material breach, but only after undergoing a dispute resolution process. In addition, either party may terminate the agreement if the other party ceases to do business, makes an assignment for the benefit of creditors or voluntarily files, fails to contest an involuntary filing or is adjudicated bankrupt or insolvent under bankruptcy, insolvency, receivership or similar law.
		Shared Services Agreement
		The Company entered into a shared services agreement with Oculus which was effective upon the completion of the IPO, pursuant to which Oculus will provide Ruthigen with general services, including general accounting and human resources, until the termination of agreement. Additionally, Oculus will permit the Company to access its Petaluma, California and Seattle, Washington facilities during normal business hours (subject to certain exceptions) and for the purposes described in the shared services agreement.
		Oculus shall also provide the Company with consulting and technical services. Such services shall be billable at the hourly or fixed monthly rate as set forth in the shared services agreement, which is subject to change based upon mutual written agreement between Oculus and Ruthigen. After the completion of the IPO, the Company agreed to pay invoices generated by Oculus within thirty days of receipt thereof.
		Separation Agreement
		The Company has entered into a separation agreement with Oculus that contains key provisions relating to the ongoing relationship with Oculus following the completion of the IPO. The separation agreement became effective upon the completion of the IPO and terminates on the earlier of 8.5 years following the closing of the IPO or when the parties mutually agree to terminate it. The separation agreement also contains a series of restrictions on Oculus’ ability to transfer the Ruthigen shares that Oculus owns. Oculus is restricted from transferring any of the Ruthigen shares it owns during the first year (the “Lock-Up Period”) immediately following the IPO unless it receives consent to do so from the Company’s Board of Directors and the lead underwriter in the Company’s IPO.
		Following the Lock-Up Period, transfers by Oculus of the Ruthigen shares it owns must be conducted with the consent of the board of directors or within the prescribed requirements for such transfers set forth in the separation agreement. These prescribed requirements include that the transfers must be in private placement transactions, the purchase price discount may not exceed certain percentages depending on the transferee, the amount of shares transferred in a given transfer (or series of transfers comprising a single transaction) may not exceed the greater of 5% of the Company’s outstanding shares or $1,500,000 in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. In addition to the manner described above, if, following a minimum of 41.5 months following the closing of the IPO have lapsed and Oculus has not consummated transfers of the Ruthigen shares it owns resulting in at least $3.8 million in net proceeds to Oculus, then Oculus has a one-time transfer and registration right to transfer the Ruthigen shares it owns in an amount equal to the difference between $3.8 million and the proceeds received by Oculus from prior transfers as of the time Oculus elects to exercise its one-time right. Transfers conducted using this one-time right must be conducted with the consent of the Company’s board of directors or within the prescribed requirements for such transfers set forth in the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the amount of shares transferred may not exceed $3,800,000 in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. The separation agreement provides Oculus with certain “piggy back” registration rights of up to 30% of the value of the securities the Company registers after the lock-up period, if the Company proposes to register any of its common stock following the completion of the IPO, subject to certain conditions and limitations.
		The separation agreement also provides for certain cooling off periods between market attempts and/or successful transfers, the length of which are dependent upon whether and the quantity of the Ruthigen shares that Oculus transfers. The majority of the material restrictions and obligations contained in the separation agreement lapse if and when Oculus own less than 19.9% of the outstanding shares of the Company’s common stock.
		The separation agreement also defined the methodology for the allocation of the operational and IPO related expenses incurred prior to and in connection with the IPO for which the Company was required to reimburse Oculus. The Company will also reimburse Oculus for expenses such as salaries and benefits advanced or paid on the Company’s behalf or for the Company’s benefit during a transition period following the closing of the IPO. During the year ended March 31, 2014, the Company incurred $1,450,000 of IPO and other costs which were reimbursed to Oculus at the closing of the IPO or shortly thereafter.
		The separation agreement provides that each party will indemnify, defend and hold harmless the other party and its affiliates for third party claims asserted against the other party. The separation agreement also provides that, so long as Oculus maintains a directors’ and officers’ insurance program covering the past and present officers and directors of Oculus, the program shall be standard in Oculus’ industry and Oculus shall not exclude any former Oculus director from any insurance policy coverage.
		Funding Agreement
		On January 31, 2014, the Company entered into a funding agreement with Oculus, pursuant to which Oculus agreed to fund the Company in the additional amount of up to $760,000 to pay certain accounts payables outstanding at December 31, 2013 and to fund certain future expenditures through the closing of the IPO. Through the closing of the IPO, Oculus funded the Company in the additional amount of $534,000, which was repaid to Oculus on April 1, 2014.
		Operating Lease
		The Company leases a facility in Santa Rosa, California under a non-cancelable operating lease for approximately 995 square feet of executive office space. The lease expires in October 2014 and monthly rent is approximately $1,700. The aggregate base rent payable over the lease term is being recognized on a straight-line basis. Rent expense amounted to approximately $20,000 and $17,000 for the years ended March 31, 2014 and 2013, respectively. Rent expense is reflected in selling, general and administrative expenses in the statements of operations.
		Future minimum payments under the operating lease agreement are as follows:
		For the Years Ending March 31,	Amount
		2015	$	11,813

Stockholders_Equity

Stockholders' Equity	9 Months Ended											12 Months Ended
	Dec. 31, 2014											Mar. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 6. Stockholders’ Equity											Note 6. Stockholders’ Equity
	Initial Public Offering											Authorized Capital
	The Company closed its IPO of the sale of 2,650,000 Units at a price of $7.25 per Unit on March 26, 2014. Following the closing of the IPO, during the nine months ended December 31, 2014 and in connection with its IPO, the underwriters exercised a portion of the over-allotment option pursuant to which the Company sold an additional 154,290 shares of common stock at $6.6608 per share, which resulted in approximately $1,028,000 of aggregate net proceeds to the Company. In connection with the underwriters’ partial exercise of the over-allotment option, the Company issued to the representative of the underwriters a five-year warrant to purchase an additional 5,400 shares of the Company’s common stock at an exercise price of $9.0625 per share. The warrant is exercisable commencing one year from the date of issuance. The warrant and the shares of common stock underlying the warrant have been deemed compensation by Financial Industry Regulatory Authority, Inc. (“FINRA”) and are, therefore, subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA.											The Company is authorized to issue up to 100,000,000 shares of common stock with a par value of $0.0001 per share and 500,000 shares of preferred stock with a par value of $0.0001 per share.
	Stock Warrants											Description of Common Stock
	A summary of the warrant activity during the nine months ended December 31, 2014 is presented below:											Each share of common stock has the right to one vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.
												2013 Plan
												In September and October 2013, respectively, the Company’s board of directors and stockholders approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”), which became effective upon the closing of the IPO. The 2013 Plan will expire on September 30, 2023. Under the 2013 Plan, the Company may grant incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards. There are 998,355 shares of the Company’s common stock authorized for issuance under the 2013 Plan. The Company intends to issue new shares of common stock to satisfy 2013 Plan obligations.
		Number of			Weighted		Weighted			Intrinsic		In addition, the 2013 Plan contains an “evergreen” provision, which allows for an annual increase in the number of shares of the Company’s common stock available for issuance under the 2013 Plan on the first day of each calendar year beginning with calendar year 2015. The annual increase in the number of shares shall be equal to the lowest of: (a) 232,500 shares of the Company’s common stock; (b) 5% of the number of shares of the Company’s common stock outstanding as of such date; and (c) an amount determined by the Company’s board of directors or compensation committee.
		Warrants			Average		Average			Value		Initial Public Offering
					Exercise		Remaining					On March 21, 2014, the Company announced that it had priced its IPO of 2,650,000 units (the “IPO”), with each unit consisting of (i) one share of common stock and (ii) one Series A warrant (the “Series A Warrant”), at an IPO price of $7.25 per unit (each a “Unit”), less underwriting discounts and commissions and IPO expenses. In addition, the Company granted to the underwriters a 45-day option (the “Over-Allotment Option”) to purchase up to (i) 397,500 additional shares of common stock at price of $6.6608 per share, which price reflects underwriting discounts and commissions, and/or (ii) 397,500 additional Series A Warrants at a price of $0.0092 per Series A Warrant, which price reflects underwriting discounts and commissions.
					Price		Life					On March 26, 2014, the Company closed on the sale of 2,650,000 Units and the underwriters exercised a portion of the Over-Allotment Option by purchasing Series A Warrants from the Company to purchase 397,500 shares of common stock for nominal value, all of which resulted in $16,021,000 of aggregate net proceeds to the Company ($19,216,000 of gross proceeds less $3,195,000 of issuance costs). As a result, an aggregate of 2,650,000 shares of common stock and Series A Warrants to purchase an aggregate of 3,047,500 shares of common stock were issued in the IPO.
							In Years					The Series A Warrant is exercisable at a price of $7.25 per warrant for (x) one share of common stock and (y) one Series B warrant (the “Series B Warrant”) to purchase one share of common stock at an exercise price of $9.0625 per share. The Series A Warrants are exercisable on the date of issuance and terminate on the second anniversary of the date of issuance. The exercise price and the number of shares for which each Series A Warrant may be exercised is subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company’s common stock. In addition, subject to certain exceptions, the exercise price of the Series A Warrants is subject to a weighted average reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below both (a) the current exercise price of the Series A Warrant; and (b) the current market price of the Company’s common stock. The Series A Warrants may be called by the Company, for consideration equal to $0.0001 per Series A Warrant, on not less than 10 business days’ notice if the closing price of the common stock is above 150% of the $7.25 IPO price per unit for any period of 20 consecutive business days ending not more than three business days prior to the call notice date. The Series B Warrants will be exercisable on the date that the warrants are issued and will terminate on the fifth anniversary of the date the warrants are first exercisable. The Company agrees that, during the period the Series A Warrants are outstanding, it will maintain the effectiveness of the registration statement such that the holder may exercise the Series A Warrants to receive registered shares of common stock and registered Series B Warrants (and the shares of common stock underlying the Series B Warrants). The Company determined that the Series A and Series B Warrants are equity instruments because the warrants are (a) freestanding financial instruments; (b) indexed to the Company’s own stock; (c) not permitted to be settled for cash; and (d) exercisable into common stock for which the Company has sufficient authorized and unissued shares.
	Outstanding, March 31, 2014		3,140,250		$	7.3						The Company issued to the representative of the underwriters warrants to purchase 92,750 shares of the Company’s common stock at an exercise price of $9.0625 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable commencing on March 21, 2015 and expiring on March 21, 2019. The Representative’s Warrants and the shares of common stock underlying the warrants have been deemed compensation by Financial Industry Regulatory Authority, Inc. (“FINRA”) and are, therefore, subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA.
	Granted		5,400			9.06						The Company, its officers and directors and its Former Parent have entered into lock-up agreements with the underwriters. Under these agreements, the Company and the other parties have agreed, subject to specified exceptions, not to sell or transfer any common stock or securities convertible into, or exchangeable or exercisable for, common stock, during a period ending 180 days after the date of its prospectus (one year for the shares of common stock owned by the Company’s Former Parent), without first obtaining the written consent of representative of the underwriters. The lock up period for the Company, its officers and directors is subject to extension for up to an additional 18 days upon the occurrence of certain specified events.
	Exercised		—			—						Investment from Former Parent
	Forfeited		—			—						During the years ended March 31, 2014 and 2013, the Company’s Former Parent made capital contributions to the Company in the amount of $1,679,000 and $570,000, respectively, which were recorded as additional paid-in capital in the statement of changes in stockholders’ equity. See Note 7 Related Party Transactions for details associated with the Former Parent’s ownership interest in the Company.
	Outstanding, December 31, 2014		3,145,650		$	7.31		1.3		$	—	Stock Warrants
	Exercisable, December 31, 2014		3,047,500		$	7.25		1.2		$	—	A summary of the warrant activity during the years ended March 31, 2014 and 2013 is presented below:
	The following table presents information related to stock warrants at December 31, 2014:
													Number of		Weighted		Weighted		Intrinsic
		Warrants Outstanding					Warrants Exercisable						Warrants		Average		Average		Value
		Exercise			Outstanding		Weighted Average			Exercisable					Exercise		Remaining
		Price			Number of		Remaining Life			Number of					Price		Life
					Warrants		In Years			Warrants							In Years
		$	7.25			3,047,500		1.2			3,047,500	Outstanding, March 31, 2012		—	$	—
		$	9.0625			98,150		—			—	Granted		—		—
						3,145,650		1.2			3,047,500	Exercised		—		—
	Stock Options											Forfeited		—		—
	The Company has computed the fair value of options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate of 0% for options unvested during the nine months ended December 31, 2014. The expected term used for options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.											Outstanding, March 31, 2013		—		—
	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:											Granted		3,140,250		7.3
												Exercised		—		—
												Forfeited		—		—
		For the Nine Months Ended										Outstanding, March 31, 2014		3,140,250	$	7.3		2.1	$	—
												Exercisable, March 31, 2014		3,047,500	$	7.25		2	$	—
		December 31,										The following table presents information related to stock warrants at March 31, 2014:
		2014			2013
	Risk free interest rate		1.67	%		n/a
	Expected term (years)		5.61			n/a							Warrants Outstanding				Warrants Exercisable
	Expected volatility		95	%		n/a							Exercise		Outstanding		Weighted		Exercisable
	Expected dividends		0	%		n/a							Price		Number of		Average		Number of
	The weighted average estimated fair value of the options granted during the nine months ended December 31, 2014 was $4.79 per share. There were no options granted during the three months ended December 31, 2014 and the three and nine months ended December 31, 2013.														Warrants		Remaining Life		Warrants
	On May 12, 2014, the Company granted options to employees and directors to purchase an aggregate of 332,500 shares of common stock at an exercise price of $6.37 per share, pursuant to the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”). The shares vest ratably over three years on a quarterly basis. The aggregate grant date value of $1,593,000 will be recognized proportionate to the vesting period.																In Years
	The Company recorded stock–based compensation expense related to stock options of $133,000 and $332,000 during the three and nine months ended December 31, 2014, respectively, and $0 during the three and nine months ended December 31, 2013. As of December 31, 2014, there was $1,261,000 of unrecognized stock-based compensation expense related to stock options that will be amortized over a weighted average period of 2.4 years.												$	7.25		3,047,500		2		3,047,500
	A summary of the stock option activity during the nine months ended December 31, 2014 is presented below:												$	9.0625		92,750		—		—
																3,140,250		2		3,047,500
		Number of			Weighted		Weighted			Intrinsic
		Options			Average		Average			Value
					Exercise		Remaining
					Price		Life
							In Years
	Outstanding, March 31, 2014		—		$	—
	Granted		332,500			6.37
	Exercised		—			—
	Forfeited		—			—
	Outstanding, December 31, 2014		332,500		$	6.37		9.4		$	—
	Exercisable, December 31, 2014		55,412		$	6.37		9.4		$	—
	The following table presents information related to stock options at December 31, 2014:
		Options Outstanding					Options Exercisable
		Exercise			Outstanding		Weighted			Exercisable
		Price			Number of		Average			Number of
					Options		Remaining Life			Options
							In Years
		$	6.37			332,500		9.4			55,412
						332,500		9.4			55,412
Restricted Stock Units
On May 11, 2014, the Company granted RSUs issuable for an aggregate of 409,355 shares to employees and directors, pursuant to the 2013 Plan. RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.
The Company recorded stock–based compensation expense related to RSUs of $179,000 and $447,000 during the three and nine months ended December 31, 2014, respectively, and $0 during the three and nine months ended December 31, 2013. As of December 31, 2014, there was $1,701,000 of unrecognized stock-based compensation expense related to RSUs that will be amortized over a weighted average period of 2.4 years. The Company recognizes stock-based compensation expense for RSUs with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. As of December 31, 2014, the Company has not recognized any expense related to RSUs with performance conditions. As of December 31, 2014, there was $431,000 of unrecognized stock-based compensation expense related to RSUs with performance conditions.
A summary of RSU activity for the nine months ended December 31, 2014 is presented below:
	Number of			Weighted		Total
	Units			Average		Grant Date
				Grant Date		Fair Value
				Fair Value
Non-vested, March 31, 2014		—		$	—	$	—
Granted		409,355			6.3		2,579,000
Vested		(56,826	)		6.3		(358,000	)
Forfeited		—			—		—
Non-vested, December 31, 2014		352,529		$	6.3	$	2,221,000

Income_Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7. Income Taxes
	The Company is included in the U.S. federal and state (California) tax returns with its Former Parent through the March 26, 2014 closing date of the IPO. However, this footnote has been presented as if the Company was filing tax returns on a separate, stand-alone basis during the pre-IPO periods. Post-IPO, the Company will file separate, stand-alone tax returns.
	The following summarizes the income tax provision (benefit):
		For The Years Ended March 31,
		2014			2013
	Federal
	Current	$	—		$	—
	Deferred		(1,031,000	)		(177,000	)
	State and local
	Current		—			—
	Deferred		(182,000	)		(26,000	)
			(1,213,000	)		(203,000	)
	Change in valuation allowance		1,213,000			203,000
	Income tax provision (benefit)	$	—		$	—
	The Company has the following net deferred tax assets:
		For The Years Ended March 31,
		2014			2013
	Expected federal statutory rate		(34.0	)%		(34.0	)%
	State tax rate, net of federal benefit		(6.0	)%		(4.8	)%
	Change in effective state tax rate		(0.3	)%		0	%
	Other permanent		1.3	%		0	%
	Change in valuation allowance		39	%		38.8	%
	Income tax provision (benefit)		0	%		0	%
	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		March 31,
		2014			2013
	Net operating loss carryforwards	$	1,427,000		$	214,000
	Valuation allowance		(1,427,000	)		(214,000	)
	Net deferred tax assets	$	—		$	—
	For the years ended March 31, 2014 and 2013, the Company had approximately $3,567,000 and $551,000 of federal and state net operating loss carryovers (“NOLs”), respectively, which begin to expire if not utilized in 2033. These net operating loss carryovers are subject to annual limitations under Internal Revenue Code Section 382 because there was a greater than 50% ownership change in connection with the March 26, 2014 closing of the IPO.
	The Company, after considering all available evidence, fully reserved its deferred tax assets since it is more likely than not that such benefits will not be realized in future periods. The Company has incurred losses for both financial reporting and income tax purposes for the years ended March 31, 2014 and 2013. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could affect the realization of their future benefit. If it is determined in future periods that portions of the Company’s deferred tax assets satisfy the realization standards, the valuation allowance will be reduced accordingly.
	The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will increase or decrease within 12 months of March 31, 2014. The unrecognized tax benefits may increase or change during the next year for items that arise in the ordinary course of business. The earliest Former Parent tax returns that include the Company’s carryforward NOLs, which remain subject to examination by tax authorities are those for the fiscal period ended March 31, 2013. The Company has elected to reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 8. Related Party Transactions
	Upon completion of the IPO, on March 26, 2014, the Former Parent owned approximately 43% of the Company’s common stock.
	During the year ended March 31, 2013, the Company contracted with a direct member of the Chief Executive Officer’s family to provide marketing services, including but not limited to brand management of the Company’s website, name and logo development. The family member was paid $6,000 for services completed.
	Beginning in March 2013, the Company employed an immediate family member of the Chief Executive Officer as an operations technician at an annualized salary of approximately $36,000.

Subsequent_Events

Subsequent Events	12 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 9. Subsequent Events
	Initial Public Offering
	Subsequent to March 31, 2014, in connection with the IPO, the underwriters exercised a portion of the Over-Allotment Option pursuant to which the Company sold an additional 154,290 shares of common stock, which resulted in $1,028,000 of aggregate gross proceeds to the Company. As of the date of this filing, the IPO has terminated.
	Stock-Based Compensation
	On May 11, 2014, the Company granted restricted stock units exercisable for an aggregate of 409,355 shares (“RSUs”) to employees and directors, pursuant to the 2013 Plan. RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and RSUs for 68,355 shares vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.
	On May 12, 2014, the Company granted options to employees and directors to purchase an aggregate of 332,500 shares of common stock at an exercise price of $6.37 per share, pursuant to the 2013 Plan. The shares vest ratably over three years on a quarterly basis.
	Employment Agreement
	On June 24, 2014, the compensation committee of the Company’s board of directors approved an employment agreement for its Chief Financial Officer (“CFO”), which replaced the offer letter previously in effect between the Company and the CFO. The employment agreement continues to provide for an annual base salary of $225,000, subject to increase, as determined by the Company’s board of directors. The employment agreement further provides for payments to the CFO in the event of termination without cause or resignation by the CFO for good reason, as such terms are defined in the employment agreement. In the event that the CFO is terminated without cause or resigns for good reason, the CFO is entitled to: (i) a lump severance payment equal to 18 times the average monthly base salary paid to the CFO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CFO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event the CFO resigns for good reason prior to a change of control, only the vesting of the restricted stock units granted by the Company on May 12, 2014 shall be accelerated.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended					12 Months Ended
	Dec. 31, 2014					Mar. 31, 2014
Accounting Policies [Abstract]
Liquidity Disclosure [Policy Text Block]	Liquidity and Financial Condition					Liquidity and Financial Condition
	The Company incurred net losses of $1,712,000 and $5,137,000 for the three and nine months ended December 31, 2014, respectively, and $658,000 and $2,129,000 for the three and nine months ended December 31, 2013, respectively. At December 31, 2014, the Company’s working capital and accumulated deficit were $11,194,000 and $8,806,000, respectively. The Company has not yet achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.					The Company incurred a net loss of $3,118,000 and $523,000 for the years ended March 31, 2014 and 2013, respectively. At March 31, 2014, the Company’s working capital and accumulated deficit were $14,627,000 and $3,669,000, respectively. The Company has not yet achieved profitability and it is expected that research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.
	The Company believes that its existing cash, which includes the proceeds from its initial public offering (“IPO”), will be sufficient to fund its operations through the quarter ending March 31, 2016. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means. The Company has not secured any commitment for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.					Subsequent to March 31, 2014, in connection with the exercise of the Over-Allotment Option (as defined in Note 6) by the lead underwriter in the Company’s IPO, 154,290 shares of common stock were sold for $1,028,000 of aggregate gross proceeds to the Company. The Company believes that its existing cash, which includes the proceeds from its IPO, will be sufficient to fund its operations into the quarter ending December 31, 2015. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means.
						The Company has not secured any commitment for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates					Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to the Company’s deferred tax assets and the expense allocations relating to the Company’s operations prior to its deconsolidation from Oculus Innovative Sciences, Inc. (“Oculus” or “Former Parent”) on March 26, 2014.					The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the expense allocations from the Former Parent and the valuation allowance related to the Company’s deferred tax assets.
Concentration Risk, Credit Risk, Policy [Policy Text Block]						Concentration of Credit Risk
						Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash. Cash is maintained in financial institutions located in the United States. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits.
Fair Value Measurement, Policy [Policy Text Block]						Fair Value of Financial Assets and Liabilities
						Financial instruments, including cash, accounts payable and accrued expenses are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
						The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value:
						Level 1 — quoted prices in active markets for identical assets or liabilities.
						Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.
						Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions).
Property, Plant and Equipment, Policy [Policy Text Block]						Property and Equipment
						Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification is as follows:
								Years
						Office Equipment		3
						Manufacturing, lab and other equipment		5
						Furniture and fixtures		7
						Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]						Impairment of Long-Lived Assets
						The Company periodically reviews the carrying values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment include, but are not necessarily limited to:
							•	a significant decrease in the fair value of an asset;
							•	a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;
							•	a significant adverse change in legal factors or in the business climate that affects the value of an asset;
							•	an adverse action or assessment by the U.S. Food and Drug Administration or another regulator;
							•	an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.
						When circumstances indicate that an impairment may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation					Stock-Based Compensation
	The Company accounts for share-based awards exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Company estimates the fair value of restricted stock and restricted stock units (“RSUs”) based upon the closing market price of the Company’s common stock on the date the award is granted. The Company amortizes the fair value of employee awards on a straight-line basis over the requisite service period of the awards. Stock-based compensation expense includes the impact of an estimate for forfeitures for all stock awards. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.					The Company accounts for share-based awards exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock awards using the Black-Scholes valuation model. The Company amortizes the fair value of employee stock awards on a straight-line basis over the requisite service period of the awards. Compensation expense includes the impact of an estimate for forfeitures for all stock awards.
	The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over the requisite service period.					The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over the requisite service period.
Research and Development Expense, Policy [Policy Text Block]						Research and Development
						Research and development expense is charged to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share					Net Loss per Share
	The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable.					The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:					As of March 31, 2014, outstanding stock warrants to purchase 3,140,250 shares of common stock were excluded from the calculation of diluted net loss per common share because their impact would have been anti-dilutive. As of March 31, 2013, the Company did not have any potentially dilutive securities outstanding.
		December 31,
		2014		2013
	Options		332,500		—
	Warrants		3,145,650		—
	Restricted stock units		352,529		—
	Total		3,830,679		—
Income Tax, Policy [Policy Text Block]						Income Taxes
						The Company accounts for income taxes under Accounting Standards Codification (“ASC”) 740 Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
						ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
						Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company’s financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company’s financial condition, results of operations or cash flows.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements					Recent Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation — Stock Compensation” as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its financial statements.					In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.” This ASU removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company has elected to adopt this ASU effective with this Annual Report on Form 10-K and its adoption resulted in the removal of previously required development stage disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The guidance, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company does not believe adoption of this ASU will have a material effect on its condensed financial statements.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events					Subsequent Events
	Management has evaluated subsequent events or transactions occurring through the date these condensed financial statements were issued.					Management has evaluated subsequent events or transactions occurring through the date these financial statements were issued (See Note 9 Subsequent Events).

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended					12 Months Ended
	Dec. 31, 2014					Mar. 31, 2014
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		December 31,
		2014		2013
	Options		332,500		—
	Warrants		3,145,650		—
	Restricted stock units		352,529		—
	Total		3,830,679		—
Property Plant And Equipment Useful Life [Table Text Block]						Estimated useful asset life by classification is as follows:
							Years
						Office Equipment	3
						Manufacturing, lab and other equipment	5
						Furniture and fixtures	7

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following:
		March 31,
		2014			2013
	Office Equipment	$	4,000		$	4,000
	Less: accumulated depreciation and amortization		(2,000	)		—
	Total	$	2,000		$	4,000

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]	Prepaid expenses and other current assets consists of the following:
		December 31,		March 31,
		2014		2014
		(unaudited)
	Prepaid insurance	$	114,000	$	—
	Deposits		50,000		1,000
	Prepaid rent		1,000		2,000
	Other prepaid expenses and current assets		34,000		—
	Total	$	199,000	$	3,000

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended					12 Months Ended
	Dec. 31, 2014					Mar. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses consists of the following:					Accounts payable and accrued expenses consist of the following:
		December 31,		March 31,			March 31,
		2014		2014			2014		2013
		(unaudited)				Accrued employee compensation	$	109,000	$	40,000
	Accrued employee compensation	$	72,000	$	109,000	Accrued director compensation		50,000		—
	Accrued director compensation		20,000		50,000	Accrued legal fees		183,000		18,000
	Accrued legal fees		75,000		183,000	Other accrued expenses		68,000		43,000
	Accrued professional fees		160,000		45,000	Total	$	410,000	$	101,000
	Accrued research and development		231,000		9,000
	Other accrued expenses		16,000		14,000
	Total	$	574,000	$	410,000

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum payments under the operating lease agreement are as follows:
	For the Years Ending March 31,	Amount
	2015	$	11,813

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended											12 Months Ended
	Dec. 31, 2014											Mar. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule Of Share-Based Compensation, Warrant, Activity [Table Text Block]	A summary of the warrant activity during the nine months ended December 31, 2014 is presented below:											A summary of the warrant activity during the years ended March 31, 2014 and 2013 is presented below:
		Number of			Weighted		Weighted			Intrinsic			Number of		Weighted		Weighted		Intrinsic
		Warrants			Average		Average			Value			Warrants		Average		Average		Value
					Exercise		Remaining								Exercise		Remaining
					Price		Life								Price		Life
							In Years										In Years
	Outstanding, March 31, 2014		3,140,250		$	7.3						Outstanding, March 31, 2012		—	$	—
	Granted		5,400			9.06						Granted		—		—
	Exercised		—			—						Exercised		—		—
	Forfeited		—			—						Forfeited		—		—
	Outstanding, December 31, 2014		3,145,650		$	7.31		1.3		$	—	Outstanding, March 31, 2013		—		—
	Exercisable, December 31, 2014		3,047,500		$	7.25		1.2		$	—	Granted		3,140,250		7.3
												Exercised		—		—
												Forfeited		—		—
												Outstanding, March 31, 2014		3,140,250	$	7.3		2.1	$	—
												Exercisable, March 31, 2014		3,047,500	$	7.25		2	$	—
Schedule Of Share Based Compensation, Warrants, By Exercise Price Range [Table Text Block]	The following table presents information related to stock warrants at December 31, 2014:											The following table presents information related to stock warrants at March 31, 2014:
		Warrants Outstanding					Warrants Exercisable						Warrants Outstanding				Warrants Exercisable
		Exercise			Outstanding		Weighted Average			Exercisable			Exercise		Outstanding		Weighted		Exercisable
		Price			Number of		Remaining Life			Number of			Price		Number of		Average		Number of
					Warrants		In Years			Warrants					Warrants		Remaining Life		Warrants
		$	7.25			3,047,500		1.2			3,047,500						In Years
		$	9.0625			98,150		—			—		$	7.25		3,047,500		2		3,047,500
						3,145,650		1.2			3,047,500		$	9.0625		92,750		—		—
																3,140,250		2		3,047,500
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
		For the Nine Months Ended
		December 31,
		2014			2013
	Risk free interest rate		1.67	%		n/a
	Expected term (years)		5.61			n/a
	Expected volatility		95	%		n/a
	Expected dividends		0	%		n/a
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the nine months ended December 31, 2014 is presented below:
		Number of			Weighted		Weighted			Intrinsic
		Options			Average		Average			Value
					Exercise		Remaining
					Price		Life
							In Years
	Outstanding, March 31, 2014		—		$	—
	Granted		332,500			6.37
	Exercised		—			—
	Forfeited		—			—
	Outstanding, December 31, 2014		332,500		$	6.37		9.4		$	—
	Exercisable, December 31, 2014		55,412		$	6.37		9.4		$	—
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at December 31, 2014:
		Options Outstanding					Options Exercisable
		Exercise			Outstanding		Weighted			Exercisable
		Price			Number of		Average			Number of
					Options		Remaining Life			Options
							In Years
		$	6.37			332,500		9.4			55,412
						332,500		9.4			55,412
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	A summary of RSU activity for the nine months ended December 31, 2014 is presented below:
		Number of			Weighted		Total
		Units			Average		Grant Date
					Grant Date		Fair Value
					Fair Value
	Non-vested, March 31, 2014		—		$	—	$	—
	Granted		409,355			6.3		2,579,000
	Vested		(56,826	)		6.3		(358,000	)
	Forfeited		—			—		—
	Non-vested, December 31, 2014		352,529		$	6.3	$	2,221,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The following summarizes the income tax provision (benefit):
		For The Years Ended March 31,
		2014			2013
	Federal
	Current	$	—		$	—
	Deferred		(1,031,000	)		(177,000	)
	State and local
	Current		—			—
	Deferred		(182,000	)		(26,000	)
			(1,213,000	)		(203,000	)
	Change in valuation allowance		1,213,000			203,000
	Income tax provision (benefit)	$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The Company has the following net deferred tax assets:
		For The Years Ended March 31,
		2014			2013
	Expected federal statutory rate		(34.0	)%		(34.0	)%
	State tax rate, net of federal benefit		(6.0	)%		(4.8	)%
	Change in effective state tax rate		(0.3	)%		0	%
	Other permanent		1.3	%		0	%
	Change in valuation allowance		39	%		38.8	%
	Income tax provision (benefit)		0	%		0	%
Schedule Of Reconciliation Of The Statutory Federal Income Tax Rate To The Companybs effective Tax Rate [Table Text Block]	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		March 31,
		2014			2013
	Net operating loss carryforwards	$	1,427,000		$	214,000
	Valuation allowance		(1,427,000	)		(214,000	)
	Net deferred tax assets	$	—		$	—

Organization_Details_Textual

Organization (Details Textual) (USD $)	0 Months Ended		1 Months Ended
	Sep. 25, 2013	Mar. 26, 2014	Mar. 21, 2014	Mar. 26, 2014	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Common Stock, Par or Stated Value Per Share	$0.00				$0.00	$0.00	$0.00
Common Stock, Shares, Outstanding	5,000,000				4,804,290	4,650,000	2,000,000
Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares	2,000,000
Stockholders' Equity, Reverse Stock Split	1-for-2.5 reverse stock split
IPO [Member]
Initial Public Offering Units		2,650,000	2,650,000	2,650,000
Initial Public Offering Price Per Unit		$7.25	$7.25	$7.25		$7.25

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	9 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,830,679	0	3,140,250
Employee Stock Option [Member]
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	332,500	0
Warrant [Member]
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,145,650	0
Restricted Stock Units (RSUs) [Member]
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	352,529	0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Mar. 31, 2014
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Manufacturing Facility [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Summary Of Significant Accounting Policies [Line Items]
Net Income (Loss) Attributable to Parent	$1,712,000	$658,000	$5,137,000	$2,129,000	$3,118,000	$523,000
Working Capital	11,194,000		11,194,000		14,627,000
Retained Earnings (Accumulated Deficit)	8,806,000		8,806,000		3,669,000	551,000
Development Stage Entities, Stock Issued, Value, Issued for Cash			1,028,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			3,830,679	0	3,140,250
Over-Allotment Option [Member]
Summary Of Significant Accounting Policies [Line Items]
Development Stage Entities, Stock Issued, Shares, Issued for Cash					154,290
Development Stage Entities, Stock Issued, Value, Issued for Cash					$1,028,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Line Items]
Office Equipment		$4,000	$4,000
Less: accumulated depreciation and amortization		-2,000	0
Total	$105,000	$2,000	$4,000

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	9 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Depreciation	$0	$1,000	$2,000	$0

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid insurance	$114,000	$0
Deposits	50,000	1,000
Prepaid rent	1,000	2,000
Other prepaid expenses and current assets	34,000	0
Total	$199,000	$3,000	$4,000

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Accounts Payable And Accrued Expenses [Line Items]
Accrued employee compensation	$72,000	$109,000	$40,000
Accrued director compensation	20,000	50,000	0
Accrued legal fees	75,000	183,000	18,000
Accrued professional fees	160,000	45,000
Accrued research and development	231,000	9,000
Other accrued expenses	16,000	14,000	43,000
Total	$574,000	$410,000	$101,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Mar. 31, 2014
Future Minimum Rental Payments For Operating Leases [Line Items]
2015	$11,813

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	12 Months Ended		0 Months Ended	9 Months Ended	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Aug. 12, 2013	Dec. 31, 2014	Nov. 28, 2014	Jun. 24, 2014	Apr. 02, 2014	Jan. 31, 2014
	sqft	sqft
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense	$1,700	$20,000	$17,000
Lease Expiration Date			31-Oct-14
Executive Office space	995	995
Oculus [Member]
Commitments And Contingencies [Line Items]
Description Of Separation Agreement		separation agreement became effective upon the completion of the IPO and terminates on the earlier of 8.5 years following the closing of the IPO or when the parties mutually agree to terminate it.
Minimum Duration For Shares Transfer		41 months 15 days
Proceeds From Transfer Atleast For Not Consummated		3,800,000
Share Transfer Agreement Terms		Transfers conducted using this one-time right must be conducted with the consent of the Companys board of directors or within the prescribed requirements for such transfers set forth in the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the amount of shares transferred may not exceed $3,800,000 in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. The separation agreement provides Oculus with certain piggy back registration rights of up to 30%
Percentage Of Outstanding Shares For Laps of Transfer		19.90%
Reimbursement Of Expenses Related To Transfer		1,450,000
Fund To Pay Certain Account Payables Outstanding								534,000	760,000
Oculus [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Percentage Of Shares Transfer By Former Parent		5.00%
Consideration For Shares Transfer By Parent		1,500,000
Chief Executive Officer [Member]
Commitments And Contingencies [Line Items]
Cash Bonus				158,000
Two Executives [Member]
Commitments And Contingencies [Line Items]
Severance Costs					1,144,000
Employee Agreement [Member] | Chief Executive Officer [Member]
Commitments And Contingencies [Line Items]
Officers' Compensation						375,000
Deferred Compensation Arrangement with Individual, Description					(i) a lump severance payment equal to 24 times the average monthly base salary paid to the CEO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CEO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards.
Employee Agreement [Member] | Chief Financial Officer [Member]
Commitments And Contingencies [Line Items]
Officers' Compensation							225,000
Deferred Compensation Arrangement with Individual, Description					(i) a lump severance payment equal to 18 times the average monthly base salary paid to the CFO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CFO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event the CFO resigns for good reason prior to a change of control, only the vesting of the restricted stock units granted by the Company on May 12, 2014 shall be accelerated.
License And Supply Agreement [Member]
Commitments And Contingencies [Line Items]
Supply Commitment, Remaining Minimum Amount Committed	8,000,000	8,000,000
Purchase Commitment, Description		Oculus shall manufacture and supply, at a purchase price equal to 20% over the cost of goods to Oculus
License And Supply Agreement [Member] | First Phase member [Member]
Commitments And Contingencies [Line Items]
Cost of Services, Licenses and Services		1,500,000
License And Supply Agreement [Member] | Second Phase member [Member]
Commitments And Contingencies [Line Items]
Cost of Services, Licenses and Services		1,500,000
License And Supply Agreement [Member] | Third Phase member [Member]
Commitments And Contingencies [Line Items]
Cost of Services, Licenses and Services		3,000,000
License And Supply Agreement [Member] | Fourth Phase member [Member]
Commitments And Contingencies [Line Items]
Cost of Services, Licenses and Services		2,000,000
License And Supply Agreement [Member] | Minimum [Member]
Commitments And Contingencies [Line Items]
Royalty Guarantees, Commitments, Percentage		3.00%
License And Supply Agreement [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Royalty Guarantees, Commitments, Percentage		20.00%
License And Supply Agreement [Member] | Oculus [Member]
Commitments And Contingencies [Line Items]
Supply Commitment, Remaining Minimum Amount Committed					$8,000,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, March 31, 2014	3,140,250
Number of Warrants Outstanding, December 31, 2014	3,145,650	3,140,250
Number of Warrants Exercisable, December 31, 2014	3,047,500	3,047,500
Weighted Average Exercise Price Exercisable, December 31, 2014		$7.25
Warrants Exercisable Weighted Average Remaining Life	1 year 2 months 12 days	2 years
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, March 31, 2014	3,140,250	0	0
Number of Warrants Granted	5,400	3,140,250	0
Number of Warrants Exercised	0	0	0
Number of Warrants Forfeited	0	0	0
Number of Warrants Outstanding, December 31, 2014	3,145,650	3,140,250	0
Number of Warrants Exercisable, December 31, 2014	3,047,500	3,047,500
Weighted Average Exercise Price Outstanding, March 31, 2014	$7.30	$0	$0
Weighted Average Exercise Price Granted	$9.06	$7.30	$0
Weighted Average Exercise Price, Exercised	$0	$0	$0
Weighted Average Exercise Price Forfeited	$0	$0	$0
Weighted Average Exercise Price Outstanding, December 31, 2014	$7.31	$7.30	$0
Weighted Average Exercise Price Exercisable, December 31, 2014	$7.25	$7.25
Weighted Average Remaining Life Outstanding, December 31, 2014	1 year 3 months 18 days	2 years 1 month 6 days
Warrants Exercisable Weighted Average Remaining Life	1 year 2 months 12 days	2 years
Intrinsic Value Outstanding, December 31, 2014	$0	$0
Intrinsic Value Exercisable, December 31, 2014	$0	$0

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding Exercise Price		$9.06
Warrants Outstanding Number of Warrants	3,145,650	3,140,250
Warrants Exercisable Weighted Average Remaining Life	1 year 2 months 12 days	2 years
Warrants Exercisable Number of Warrants	3,047,500	3,047,500
Exercise Price Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding Exercise Price	$7.25	$7.25
Warrants Outstanding Number of Warrants	3,047,500	3,047,500
Warrants Exercisable Weighted Average Remaining Life	1 year 2 months 12 days	2 years
Warrants Exercisable Number of Warrants	3,047,500	3,047,500
Exercise Price Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding Exercise Price	$9.06	$9.06
Warrants Outstanding Number of Warrants	98,150	92,750
Warrants Exercisable Weighted Average Remaining Life	0 years	0 years
Warrants Exercisable Number of Warrants	0	0

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2)	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.67%
Expected term (years)	5 years 7 months 10 days
Expected volatility	95.00%
Expected dividends	0.00%

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	9 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, March 31, 2014	0
Number of Options Granted	332,500
Number of Options Exercised	0
Number of Options Forfeited	0
Number of Options Outstanding, December 31, 2014	332,500
Number of Options Exercisable, December 31, 2014	55,412
Weighted Average Exercise Price Outstanding, March 31, 2014	$0
Weighted Average Exercise Price Granted	$6.37
Weighted Average Exercise Price Exercised	$0
Weighted Average Exercise Price Forfeited	$0
Weighted Average Exercise Price Outstanding, December 31, 2014	$6.37
Weighted Average Exercise Price Exercisable, December 31, 2014	$6.37
Weighted Average Remaining Life Outstanding, December 31, 2014	9 years 4 months 24 days
Weighted Average Remaining Life Exercisable, December 31, 2014	9 years 4 months 24 days
Intrinsic Value Outstanding, December 31, 2014	$0
Intrinsic Value Exercisable, December 31, 2014	$0

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (USD $)	9 Months Ended
	Dec. 31, 2014	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Exercise Price	$6.37	$0
Options Outstanding Number of Options	332,500	0
Options Exercisable Weighted Average Remaining Life	9 years 4 months 24 days
Options Exercisable Number of Options	55,412
Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Exercise Price	$6.37
Options Outstanding Number of Options	332,500
Options Exercisable Weighted Average Remaining Life	9 years 4 months 24 days
Options Exercisable Number of Options	55,412

Stockholders_Equity_Details_5

Stockholders' Equity (Details 5) (Restricted Stock [Member], USD $)	9 Months Ended
	Dec. 31, 2014
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Units Non-vested, March 31, 2014	0
Number of Units Granted	409,355
Number of Units Vested	-56,826
Number of Units Forfeited	0
Number of Units Non-vested, December 31, 2014	352,529
Weighted Average Grant Date Fair Value Non-vested, March 31, 2014	$0
Weighted Average Grant Date Fair Value Granted	$6.30
Weighted Average Grant Date Fair Value Vested	$6.30
Weighted Average Grant Date Fair Value Forfeited	$0
Weighted Average Grant Date Fair Value Non-vested, December 31, 2014	$6.30
Total Grant Date Fair Value Non-vested, March 31, 2014	$0
Total Grant Date Fair Value Granted	2,579,000
Total Grant Date Fair Value Vested	-358,000
Total Grant Date Fair Value Forfeited	0
Total Grant Date Fair Value Non-vested, December 31, 2014	$2,221,000

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 26, 2014	Mar. 21, 2014	Mar. 26, 2014	11-May-14	12-May-14	Sep. 25, 2013	Oct. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			0
Stock Issued During Period, Value, Stock Options Exercised			$1,028,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0	$0	$4.79	$0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			1,593,000
Allocated Share-based Compensation Expense	133,000	0	332,000	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	1,261,000		1,261,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			332,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$6.37
Class of Warrant or Right, Exercise Price of Warrants or Rights					$9.06
Common Stock, Shares Authorized	100,000,000		100,000,000		100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share	$0.00		$0.00		$0.00	$0.00						$0.00
Preferred Stock, Shares Authorized	500,000		500,000		500,000	500,000
Preferred Stock, Par or Stated Value Per Share	$0.00		$0.00		$0.00	$0.00
Common Stock, Shares, Issued	4,804,290		4,804,290		4,650,000	2,000,000
Gross Proceeds From Issuance Of Common Stock And Warrants			1,117,000		19,216,000
Offering Cost			252,000		3,195,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercisable Number	3,047,500		3,047,500		3,047,500
Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercisable Weighted Average Exercise Price					$7.25
Closing Price Of Common Stock Percentage					150.00%
Investment Warrants, Exercise Price					$0.00
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number	3,145,650		3,145,650		3,140,250
Investment From Former Parent					1,679,000	570,000
IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price								$6.66
Warrants to Purchase of Common Stock			5,400					397,500	397,500
Initial Public Offering Price Per Unit					$7.25		$7.25	$7.25	$7.25
Class of Warrant or Right, Exercise Price of Warrants or Rights	$9.06		$9.06					$0.01
Initial Public Offering Units							2,650,000	2,650,000	2,650,000
Common Stock, Shares, Issued							2,650,000		2,650,000
Proceeds from Issuance of Common Stock									16,021,000
Gross Proceeds From Issuance Of Common Stock And Warrants									19,216,000
Offering Cost									3,195,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercisable Number							3,047,500		3,047,500
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	179,000	0	447,000	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	1,701,000		1,701,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period										409,355
Restricted Stock Units (RSUs) [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			431,000
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											332,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$6.37
Common Stock, Shares Authorized													998,355
Share-based Compensation Arrangement by Share-based Payment Award, Description					The annual increase in the number of shares shall be equal to the lowest of: (a) 232,500 shares of the Companys common stock; (b) 5% of the number of shares of the Companys common stock outstanding as of such date; and (c) an amount determined by the Companys board of directors or compensation committee.
Underwriters [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$9.06
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number					92,750
Class of Warrant or Right, Date from which Warrants or Rights Exercisable					21-Mar-15
Class Of Warrant Or Rights Expiring Date Warrants Or Rights Exercisable					21-Mar-19
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			154,290					397,500
Share Price	$6.66		$6.66
Initial Public Offering Units					2,650,000
Investment From Former Parent					$0	$0

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Federal
Current	$0	$0
Deferred	-1,031,000	-177,000
State and local
Current	0	0
Deferred	-182,000	-26,000
Current Income Tax Expense (Benefit)	-1,213,000	-203,000
Change in valuation allowance	1,213,000	203,000
Income tax provision (benefit)	$0	$0

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Effective Income Tax Rate Reconciliation [Line Items]
Expected federal statutory rate	-34.00%	-34.00%
State tax rate, net of federal benefit	-6.00%	-4.80%
Change in effective state tax rate	-0.30%	0.00%
Other permanent	1.30%	0.00%
Change in valuation allowance	39.00%	38.80%
Income tax provision (benefit)	0.00%	0.00%

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Reconciliation Of The Statutory Federal Income Tax Rate To The Companybs effective Tax Rate [Line Items]
Net operating loss carryforwards	$1,427,000	$214,000
Valuation allowance	-1,427,000	-214,000
Net deferred tax assets	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$3,567,000	$551,000
Operating Loss Carryforwards, Expiration Period	2033 years
IPO [Member]
Operating Loss Carryforwards [Line Items]
Equity Method Investment, Ownership Percentage	50.00%

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	12 Months Ended
	Mar. 31, 2013	Mar. 26, 2014
Former Parent [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		43.00%
Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Cost of Services	$6,000
Salaries, Wages and Officers' Compensation	$36,000

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	9 Months Ended	0 Months Ended	12 Months Ended
	Dec. 31, 2014	12-May-14	Mar. 31, 2014
Subsequent Event [Line Items]
Development Stage Entities, Stock Issued, Value, Issued for Cash	$1,028,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	332,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$6.37
Two Thousand Thirteen Plan [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		332,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$6.37
Over-Allotment Option [Member]
Subsequent Event [Line Items]
Development Stage Entities, Stock Issued, Shares, Issued for Cash			154,290
Development Stage Entities, Stock Issued, Value, Issued for Cash			1,028,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$6.37
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			On May 11, 2014, the Company granted restricted stock units exercisable for an aggregate of 409,355 shares (RSUs) to employees and directors, pursuant to the 2013 Plan. RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and RSUs for 68,355 shares vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019
Subsequent Event [Member] | Two Thousand Thirteen Plan [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		332,500
Subsequent Event [Member] | Over-Allotment Option [Member]
Subsequent Event [Line Items]
Development Stage Entities, Stock Issued, Shares, Issued for Cash			154,290
Development Stage Entities, Stock Issued, Value, Issued for Cash			$1,028,000